DDInter581 DDInter1676
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dolasetron {u} (Compound) resembles {v} (Compound) Hyoscyamine
Dolasetron {u} (Compound) resembles {v} (Compound) Atropine
Dolasetron {u} (Compound) binds {v} (Gene) CYP2D6
Dolasetron {u} (Compound) upregulates {v} (Gene) UBQLN2
Dolasetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Dolasetron {u} (Compound) causes {v} (Side Effect) Oliguria
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Dolasetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rifampicin
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Dolasetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Dolasetron (Compound) resembles Hyoscyamine (Compound)
Dolasetron (Compound) resembles Atropine (Compound)
Dolasetron (Compound) binds CYP2D6 (Gene)
Dolasetron (Compound) upregulates UBQLN2 (Gene)
Dolasetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Dolasetron (Compound) causes Oliguria (Side Effect)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Donepezil